Antibody-mediated rejection in renal allografts: lessons from pathology.

Lorraine C. Racusen, Mark Haas

Research output: Contribution to journalReview articlepeer-review

Abstract

The past 15 years have seen major advances in the understanding of the effects of anti-donor antibodies on renal allografts at various stages after transplantation. These advances have been due in large part to pathologic examination of both early and late renal allograft biopsies, including both routine histologic evaluation and immunohistology to detect complement split products. As pathologists have become increasingly adept at diagnosing antibody-mediated rejection (AMR) on allograft biopsies, substantial progress has been made in the treatment of AMR and in successful renal transplantation in recipients with pre-existing antibodies against donor blood group (ABO) and/or major histocompatibility (HLA) antigens. This article reviews the pathologic features of hyperacute, acute, and chronic AMR, including some newer findings impacting diagnosis and outcomes, and differences in the implications of similar pathologic findings in ABO- versus HLA-incompatible renal allografts.

Original languageEnglish (US)
Pages (from-to)415-420
Number of pages6
JournalClinical journal of the American Society of Nephrology : CJASN
Volume1
Issue number3
DOIs
StatePublished - May 2006

ASJC Scopus subject areas

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Fingerprint

Dive into the research topics of 'Antibody-mediated rejection in renal allografts: lessons from pathology.'. Together they form a unique fingerprint.

Cite this